Comunicados de prensa
Brainlab Multiple Metastases Planning and Other Revolutionary Software Applications Now Available in the United States
Multiple Metastases Planning and Adaptive Hybrid Surgery, part of the Brainlab Elements portfolio, receive FDA clearanceChicago, Illinois, December 19, 2014 — Brainlab, a global developer of software-driven medical technology, announced today 510(k) clearance for two software modules for radiation oncologists and neurosurgeons. Adaptive Hybrid Surgery and Automatic Brain Metastases Planning software by Brainlab round out the Brainlab portfolio and build on the company’s mission to increase access to and consistency of patient care. These intelligent shaping tools are now available in the United States after successful clinical use in several international markets.
Adaptive Hybrid Surgery by Brainlab helps physicians to balance surgical risk with radiosurgical toxicity for multi-disciplinary treatment of skull-base tumors. A complete set of automated tools enables analysis of adjuvant radiosurgery at any time, while planning and performing a surgical resection. Elements Intraoperative Structure Update captures residual tumor volumes based on points acquired inside the resection cavity. An intuitive traffic light display provides comprehensive information about tumor coverage and critical dose constraints for calculated treatment plans.
Automatic Brain Metastasis Planning software by Brainlab introduces the market to technology that consistently and rapidly generates radiosurgery plans for the efficient treatment of multiple metastases. This breakthrough technology allows clinicians to plan and treat multiple brain metastases with time and dose efficiencies while helping to minimize exposure to healthy surrounding tissue. Treatment delivery and planning time can be reduced drastically, even for as many as 10 metastatic tumors in the brain.
“FDA clearance of these software modules marks a critical milestone in the Brainlab vision of indication-specific tools,” said Stefan Vilsmeier, President and CEO of Brainlab. “We expect their capabilities, efficiency and usability to help change the way certain life-threatening diseases are treated.”
Brainlab, headquartered in Munich, develops, manufactures and markets software-driven medical technology, enabling access to advanced, less invasive patient treatments.
Core products center on information-guided surgery, radiosurgery, precision radiation therapy, digital operating room integration, and information and knowledge exchange. Brainlab technology powers treatments in radiosurgery and radiotherapy as well as numerous surgical fields including neurosurgery, orthopaedic, ENT, CMF, spine and trauma.
Privately held since its formation in 1989, Brainlab has over 5,000 systems installed in about 95 countries. Brainlab employs 1200 people in 17 offices worldwide, including 290 research & development engineers, who form a crucial part of the product development team.
To learn more, visit brainlab.com.